- Home
- BDTX
as 03-25-2025 10:31am EST
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 96.9M | IPO Year: | 2020 |
| Target Price: | $15.60 | AVG Volume (30 days): | 7.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.59 - $7.66 | Next Earning Date: | 03-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Black Diamond Therapeutics Inc. (BDTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BIOTECH GROWTH N V | BDTX | 10% Owner | Mar 19 '25 | Sell | $2.07 | 5,784,292 | $11,997,749.13 | 7,517,839 |
Latest Black Diamond Therapeutics Inc. News
BDTX Breaking Stock News: Dive into BDTX Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
5 days ago
Servier and Black Diamond sign deal for solid tumours therapy
MT Newswires
6 days ago
Sector Update: Health Care
MT Newswires
6 days ago
Top Midday Gainers
MT Newswires
6 days ago
Black Diamond Therapeutics, Servier Sign Global Licensing Deal for BDTX-4933 to Treat Solid Tumors
GlobeNewswire
6 days ago
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
MT Newswires
18 days ago
Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating
Associated Press Finance
19 days ago
Black Diamond: Q4 Earnings Snapshot
GlobeNewswire
19 days ago
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Compare BDTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDTX Black Diamond Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.